At a glance
- Originator Abbott Laboratories
- Class Anorectics; Oligopeptides
- Mechanism of Action Cholecystokinin A receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 28 Jun 1996 Discontinued-Preclinical for Obesity in USA (Unknown route)